...
首页> 外文期刊>Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association - European Renal Association >1,25-Dihydroxyvitamin D3 but not cinacalcet HCl (Sensipar/Mimpara) treatment mediates aortic calcification in a rat model of secondary hyperparathyroidism.
【24h】

1,25-Dihydroxyvitamin D3 but not cinacalcet HCl (Sensipar/Mimpara) treatment mediates aortic calcification in a rat model of secondary hyperparathyroidism.

机译:在继发性甲状旁腺功能亢进的大鼠模型中,1,25-二羟基维生素D3而非西那卡塞HCl(Sensipar / Mimpara)可以介导主动脉钙化。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Calcitriol treatment of secondary hyperparathyroidism (HPT) in chronic kidney disease (CKD) patients can lead to increased serum calcium and phosphorus, which have been associated as risk factors for vascular calcification. Cinacalcet HCl (Sensipar/Mimpara) {(alphaR)-(-)-alpha-methyl-N-[3-[3-(trifluoromethylphenyl)propyl]-1-naptha lenemethanamine hydrochloride} lowers serum parathyroid hormone (PTH), calcium, phosphorus and calcium-phosphorous (CaxP) product in stage 5 CKD dialysis patients; however, its effects on vascular calcification are unknown. METHODS: Cinacalcet HCl (10 or 1 mg/kg, p.o. gavage), 1,25-dihydroxyvitamin D(3) (0.1 microg, s.c, calcitriol) or the combination was administered daily for 26 days in a rat model of secondary HPT [5/6 nephrectomy]. After dosing, aortic calcification was determined using the von Kossa staining method. Serum PTH and blood chemistries were determined on days 0, 26 and 0, 14, 26, respectively, prior to and after dosing. RESULTS: Calcitriol-treatedrats had moderate to marked aortic calcification, whereas no significant calcification was observed in vehicle- or cinacalcet HCl-only treated groups. Co-administration of cinacalcet HCl with calcitriol did not attenuate the calcitriol-mediated increase in CaxP product or calcitriol-mediated aortic calcification. Both calcitriol and cinacalcet HCl therapy significantly reduced serum PTH levels. Calcitriol significantly elevated serum calcium, serum phosphorous and CaxP product above pretreatment levels, or those seen with vehicle or cinacalcet HCl. Cinacalcet HCl (10 or 1 mg/kg) decreased serum ionized calcium and decreased calcitriol-induced hypercalcaemia. CONCLUSION: Cinacalcet HCl and calcitriol both effectively reduce PTH, albeit via different mechanisms, but unlike calcitriol, cinacalcet HCl did not produce hypercalcaemia, an increased CaxP product or vascular calcification.
机译:背景:骨化三醇治疗慢性肾脏病(CKD)患者继发性甲状旁腺功能亢进症(HPT)可能导致血清钙和磷增加,这些已被认为是血管钙化的危险因素。盐酸西那卡塞(Sensipar / Mimpara){{alphaR)-(-)-alpha-甲基-N- [3- [3-(三(三氟甲基苯基)丙基] -1-萘甲基亚胺盐酸盐}}降低血清甲状旁腺激素(PTH),钙, 5期CKD透析患者的磷和钙磷(CaxP)产物;然而,其对血管钙化的作用尚不清楚。方法:在继发性HPT大鼠模型中,每天服用Cinacalcet HCl(10或1 mg / kg,口服管饲),1,25-二羟基维生素D(3)(0.1 microg,sc,骨化三醇)或其组合,每天服用26天。 5/6肾切除术]。给药后,使用von Kossa染色法确定主动脉钙化。在给药之前和之后分别在第0、26和0、14、26天测定血清PTH和血液化学。结果:用骨化三醇治疗的大鼠具有中度至明显的主动脉钙化,而在仅用运载体或西那卡塞盐酸盐治疗的组中未观察到明显的钙化。盐酸西那卡塞与骨化三醇的共同给药不能减弱骨化三醇介导的CaxP产物增加或骨化三醇介导的主动脉钙化。骨化三醇和西那卡塞盐酸盐治疗均显着降低血清PTH水平。骨化三醇显着升高血清钙,血清磷和CaxP产物,使其高于预处理水平,或与溶媒或西那卡塞HCl所见的水平相比。盐酸西那卡塞(10毫克/千克或1毫克/千克)降低血清离子钙并降低骨化三醇引起的高钙血症。结论:西那卡塞盐酸盐和骨化三醇均可有效降低PTH,尽管其机制不同,但与骨化三醇不同,西那卡塞盐酸盐不产生高钙血症,CaxP产物增加或血管钙化。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号